Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal”) has entered into a Term Sheet with SōRSE Technology (“SōRSE”) to develop Pascal’s cannabinoid programs. Investing in and financially supporting Pascal Biosciences’ research marks the first step for SōRSE Technology moving into medical research applications. This partnership leverages SōRSE’s industry-leading formulation technology with Pascal’s cannabinoid programs for clinical trials, led by Patrick Gray and his team of world-class medical researchers. SōRSE Technology sells and licenses a proprietary water-soluble cannabinoid emulsion technology (patent-pending) that enables increased bioavailability, accurate dosing, and over 12 months shelf stability. SōRSE Technology is science and data-driven, with 53 employees, 30 of whom specialize in R&D and Quality Assurance.
Read the full article: SōRSE Technology Partners with & Acquires Part of Cancer Research Group Pascal Biosciences for Cannabinoid Research Programs //
Source: https://www.businesswire.com/news/home/20200311005207/en/S%C5%8DRSE-Technology-Partners-Acquires-Part-Cancer-Research